JP2007509181A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509181A5
JP2007509181A5 JP2006536942A JP2006536942A JP2007509181A5 JP 2007509181 A5 JP2007509181 A5 JP 2007509181A5 JP 2006536942 A JP2006536942 A JP 2006536942A JP 2006536942 A JP2006536942 A JP 2006536942A JP 2007509181 A5 JP2007509181 A5 JP 2007509181A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
cyclopentapyrazole
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536942A
Other languages
English (en)
Japanese (ja)
Other versions
JP4533898B2 (ja
JP2007509181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/035927 external-priority patent/WO2005044816A1/en
Publication of JP2007509181A publication Critical patent/JP2007509181A/ja
Publication of JP2007509181A5 publication Critical patent/JP2007509181A5/ja
Application granted granted Critical
Publication of JP4533898B2 publication Critical patent/JP4533898B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536942A 2003-10-31 2004-10-29 トリアゾール誘導体およびその代謝関連障害の処置方法 Expired - Fee Related JP4533898B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010053852A Division JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2007509181A JP2007509181A (ja) 2007-04-12
JP2007509181A5 true JP2007509181A5 (enExample) 2010-06-17
JP4533898B2 JP4533898B2 (ja) 2010-09-01

Family

ID=34572875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006536942A Expired - Fee Related JP4533898B2 (ja) 2003-10-31 2004-10-29 トリアゾール誘導体およびその代謝関連障害の処置方法
JP2010053852A Pending JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010053852A Pending JP2010163448A (ja) 2003-10-31 2010-03-10 トリアゾール誘導体およびその代謝関連障害の処置方法

Country Status (37)

Country Link
US (2) US8637555B2 (enExample)
EP (2) EP1599469B1 (enExample)
JP (2) JP4533898B2 (enExample)
KR (1) KR100850591B1 (enExample)
CN (1) CN1867562B (enExample)
AR (1) AR046611A1 (enExample)
AT (1) ATE328880T1 (enExample)
AU (1) AU2004287861B2 (enExample)
BR (1) BRPI0415631A (enExample)
CA (1) CA2539985C (enExample)
CO (1) CO5690551A2 (enExample)
CR (1) CR8270A (enExample)
CY (1) CY1105479T1 (enExample)
DE (1) DE602004001134T2 (enExample)
DK (1) DK1599469T3 (enExample)
EA (1) EA011484B1 (enExample)
EC (1) ECSP066529A (enExample)
ES (1) ES2267077T3 (enExample)
GE (1) GEP20094801B (enExample)
HR (1) HRP20060286T3 (enExample)
IL (1) IL174042A0 (enExample)
IS (1) IS2372B (enExample)
MA (1) MA28171A1 (enExample)
MX (1) MXPA06004556A (enExample)
MY (1) MY140410A (enExample)
NO (1) NO20062509L (enExample)
NZ (1) NZ546285A (enExample)
PE (1) PE20050483A1 (enExample)
PL (1) PL1599469T3 (enExample)
PT (1) PT1599469E (enExample)
RS (1) RS20060290A (enExample)
SI (1) SI1599469T1 (enExample)
TN (1) TNSN06150A1 (enExample)
TW (1) TWI258478B (enExample)
UA (1) UA86783C2 (enExample)
WO (1) WO2005044816A1 (enExample)
ZA (2) ZA200603419B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
AU2004293415A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008519080A (ja) * 2004-11-05 2008-06-05 アリーナ ファーマシューティカルズ, インコーポレイテッド ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
HK1217488A1 (zh) 2013-02-21 2017-01-13 Adverio Pharma Gmbh {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
CA3096145A1 (en) * 2019-10-11 2021-04-11 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
AU7307101A (en) 2000-06-30 2002-01-14 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
BR0210102A (pt) 2001-06-01 2004-06-08 Hoffmann La Roche Derivados de pirimidina, triazina e pirazina como receptores de glutamato
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー TNF−α発現のN−ヘテロ環インヒビター
DE60200346T2 (de) 2001-06-27 2005-03-24 Rs Tech Corp. Neuer chiraler salen-katalysator und verfahren zur herstellung chiraler verbindungen aus racemischen epoxiden unter verwendung des neuen katalysators
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
CA2501134A1 (en) * 2002-10-10 2004-04-22 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005011677A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PE20050483A1 (es) * 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
WO2006026273A2 (en) 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008519080A (ja) 2004-11-05 2008-06-05 アリーナ ファーマシューティカルズ, インコーポレイテッド ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles

Similar Documents

Publication Publication Date Title
JP2010163448A (ja) トリアゾール誘導体およびその代謝関連障害の処置方法
US7241792B2 (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP2007509181A5 (enExample)
EP1701947B1 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
VON et al. DISORDERS THEREOF
HK1087411A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
HK1076468B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CN101087765A (zh) 稠合吡唑衍生物和其在治疗代谢相关病症的方法中的用途
MX2007007578A (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders